Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: A case series

Schizophrenia Research

Volumn 57, Issue 2-3, 2002, Pages 221-226

  Marenco, Stefano ^a   Egan, Michael F ^a   Goldberg, Terry E ^a   Knable, Michael B ^b   McClure, Robert K ^a   Winterer, Georg ^a   Weinberger, Daniel R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b Stanley Foundation   (United States)

Author keywords

AMPA; Clinical trial; CX516; Schizophrenia

Indexed keywords

6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; CLOZAPINE; LIVER ENZYME; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSKINESIA; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; MALE; NAUSEA; NEUROPSYCHOLOGY; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TIC; TREATMENT OUTCOME; VOMITING;

ADULT; ANTIPSYCHOTIC AGENTS; DIOXOLES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 0036773660     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(01)00311-5     Document Type: Article

References (21)

1. Andreasen N.C. Scale for the Assessment of Negative Symptoms (SANS). 1981;University of Iowa, Iowa City.
2. DSM-IV DSM-IV, Diagnostic and Statistical Manual of Mental Disorders. 1994;American Psychiatric Association, Washington, DC.
3. Fann W.E., Stafford J.R., Malone R.L., Frost J.D. Jr., Richman B.W. Clinical research techniques in tardive dyskinesia. Am. J. Psychiatry. 134(7):1977;759-762.
4. Goff D.C., Bagnell A.L., Perlis R.L. Glutamatergic augmentation strategies for cognitive impairment in schizophrenia. Psychiatr. Ann. 29(11):1999;649-654.
5. Goff D.C., Henderson D.C., Evins A.E., Amico E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol. Psychiatry. 45(4):1999;512-514.
6. Goff D.C., Tsai G., Levitt J., Amico E., Manoach D., Schoenfeld D.A., Hayden D.L., McCarley R., Coyle J.T. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiatry. 56(1):1999;21-27.
7. Goldberg T.E., Gold J.M. Neurocognitive functioning in patients with schizophrenia. Bloom F.E., Kupfer D.J. Psychopharmacology: The Fourth Generation of Progress. 1995;1245-1257 Raven Press, New York.
8. Hampson R.E., Rogers G., Lynch G., Deadwyler S.A. Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance. J. Neurosci. 18(7):1998;2740-2747.
9. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry. 56(1):1999;29-36.
10. Ingvar M., Ambros-Ingerson J., Davis M., Granger R., Kessler M., Rogers G.A., Schehr R.S., Lynch G. Enhancement by an ampakine of memory encoding in humans. Exp. Neurol. 146(2):1997;553-559.
11. Johnson S.A., Luu N.T., Herbst T.A., Knapp R., Lutz D., Arai A., Rogers G.A., Lynch G. Synergistic interactions between ampakines and antipsychotic drugs. J. Pharmacol. Exp. Ther. 289(1):1999;392-397.
12. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13:1987;261-276.
13. Konitsiotis S., Blanchet P.J., Verhagen L., Lamers E., Chase T.N. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology. 54(8):2000;1589-1595.
14. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B. Jr., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry. 51(3):1994;199-214.
15. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13(1):1995;9-19.
16. Larson J., Lieu T., Petchpradub V., LeDuc B., Ngo H., Rogers G.A., Lynch G. Facilitation of olfactory learning by a modulator of AMPA receptors. J. Neurosci. 15(12):1995;8023-8030.
17. Larson J., Quach C.N., LeDuc B.Q., Nguyen A., Rogers G.A., Lynch G. Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats. Brain Res. 738(2):1996;353-356.
18. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 52(12):1995;998-1007.
19. Staubli U., Perez Y., Xu F.B., Rogers G., Ingvar M., Stone-Elander S., Lynch G. Centrally active modulators of glutamate receptors facilitate the induction of long-term potentiation in vivo. Proc. Natl. Acad. Sci. U. S. A. 91(23):1994;11158-11162.
20. Tsai G., Yang P., Chung L.C., Lange N., Coyle J.T. D-serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry. 44(11):1998;1081-1089.
21. Tsai G., Yang P., Chung L., Tsai I., Tsai C., Coyle J.T. D-serine added to clozapine for the treatment of schizophrenia. Am. J. Psychiatry. 156(11):1999;1822-1825.